<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00371670</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE581C2201</org_study_id>
    <nct_id>NCT00371670</nct_id>
  </id_info>
  <brief_title>Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee</brief_title>
  <official_title>A Phase II, 12-month, Double-blind, Placebo-controlled, Dose-finding, Multicenter Study to Evaluate the Safety, Tolerability, and Disease Modifying Efficacy of Daily Oral AAE581 (10, 25 and 50 mg Tablets) in Patients With Painful Knee Osteoarthritis, Kellgren-Lawrence Grade 3 by X-ray</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will test efficacy and safety of AAE581 compared to placebo in limiting cartilage
      loss in patients with painful knee osteoarthritis which is confirmed by X-ray
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in knee cartilage volume in the target compartment after 6 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Cartilage volume in the different regions of the knee after 6 and 12 months,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Cartilage score (Whole Organ MRI Scoring system (WORMS)) in the different regions of the knee after 6 and 12 months,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Bone marrow edema score (WORMS) in the different regions of the knee after 6 and 12 months,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Joint space width after 6 and 12 months,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Markers of bone and cartilage degradation (CTX-I and CTX-II at 3, 6, 9, and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Pain (analgesic consumption, Western Ontario and McMaster Universities Osteoarthritis Index, Visual Analogue Scale, criteria of the Outcome Measures in Rheumatology Osteoarthritis-Research Society International at 1, 3, 6, 9, and 12 months</measure>
  </secondary_outcome>
  <enrollment type="Actual">223</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>balicatib (AAE581)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one knee with osteoarthritis with Kellgren-Lawrence grade 3

          -  Significant osteoarthritis pain in the knee

          -  Presence of at least one of the risk factors: obesity (BMI &gt; 28), osteoarthritis at
             other sites, knee effusion, family history of total joint replacement

        Exclusion Criteria:

          -  Women with childbearing potential

          -  Secondary osteoarthritis

          -  Treatment with intra-articular or systemic steroids

          -  Inability to undergo MRI acquisition

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Nuernberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2395</url>
    <description>Results for CAAE581C2201 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2006</study_first_submitted>
  <study_first_submitted_qc>August 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2006</study_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Knee, osteoarthritis, pain, disease modifying</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

